Soleus Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Soleus Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.5M	Sell	375,572 -275,000	-42%	-$15.1M	0.74%	39
2026 Q1	$36.8M	Sell	650,572 -669,428	-51%	-$39M	1.49%	22
2025 Q4	$78.4M	Buy	1,320,000 +429,696	+48%	+$23.4M	2.89%	8
2025 Q3	$48.2M	Sell	890,304 -12,000	-1%	-$686K	2.43%	14
2025 Q2	$49.6M	Sell	902,304 -177,000	-16%	-$10.4M	3.28%	9
2025 Q1	$76.3M	Buy	1,079,304 +77,904	+8%	+$5.24M	5.49%	5
2024 Q4	$65.8M	Buy	+1,001,400	New	+$67.1M	4.14%	4
2023 Q3	–	Sell	-57,800	Closed	-$5.01M	–	98
2023 Q2	$5.01M	Buy	+57,800	New	+$5.44M	0.56%	49

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Soleus Capital Management's BMRN Position: Q2 2026 in Review

Soleus Capital Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 42% in Q2 2026, selling an estimated $15.1M and leaving 375,572 shares worth $21.5M. The position accounts for 0.74% of the portfolio, ranked #39.

Soleus Capital Management first reported a position in BMRN in Q2 2023 and has held it in 8 quarters since. The position peaked at $78.4M in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Soleus Capital Management held 375,572 shares of BioMarin Pharmaceuticals worth $21.5M as of Q2 2026.
Soleus Capital Management sold 275,000 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $15.1M.
BioMarin Pharmaceuticals made up 0.74% of Soleus Capital Management's portfolio in Q2 2026, its #39 holding.
Soleus Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2023 and has held it in 8 quarters since.
Soleus Capital Management's BioMarin Pharmaceuticals position peaked at $78.4M in Q4 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.